地舒单抗 使用说明

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival.

Desosumab has a high affinity for RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

Desosumab has been approved for a variety of indications. The following is a brief introduction to the usage instructions of some indications of denosumab.

Prevention of bone-related events with bone metastasis from solid tumors, not used for the prevention of bone-related events in patients with multiple myeloma: subcutaneous injection (upper arm, upper thigh, or abdomen) of 120 mg once every 4 weeks, along with calcium or vitamin D infusion to prevent hypocalcemia.

Unresectable or surgical resection of giant cell tumor of bone in adults or bone-mature adolescents may cause serious complications: subcutaneous injection, 120 mg, once every 4 weeks. In the first month of treatment, 120 mg is added on the 8th and 15th days, and calcium or vitamin D is infused to prevent hypocalcemia.

Hypercalcemia of malignant tumors: subcutaneous injection, 120 mg, once every 4 weeks. During the first month of treatment, add 120 mg on the 8th and 15th days respectively.

The above data are for reference only. Please follow your doctor’s recommendations for the actual injection dose of denosumab.

Hypocalcemia must be corrected before starting treatment. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.